Cylite's overarching vision revolves around delivering comprehensive whole eye diagnostics, superior imaging quality, and accurate analytics to facilitate informed decision-making for achieving better patient outcomes. The company's most recent funding round, a Series B investment on 04 September 2019, was led by Main Sequence Ventures. With its innovative technology and commitment to advancing eye care, Cylite is poised to make a significant impact on the Ophthalmology and Optometry industries. Learn more about Cylite at www.cyliteoptics.com.
General Information
BounceWatch is an independent company data service, not affiliated with Cylite. To contact Cylite, visit cyliteoptics.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Cylite compare?
A PDF of Cylite and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Cylite soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Australia Market
Medical Devices
About Cylite
Business keywords: OCT technology, diagnostic systems, ophthalmology, optometry, imaging technology, eye diagnostics, metrology systems, optical industry, revenue generation, A-scan speeds, corneal specialists, refractive specialists, vision diagnostics, optics expertise
Funding Rounds & Investors (1)
View AllCylite Alternatives & Competitors
View All AlternativesEradicating Preventable Blindness
Pioneering the future of ocular diagnostics with next-generation imaging technologies to enhance eye...
FAQ About Cylite
Source: BounceWatch company record for Cylite, https://bouncewatch.com/company/cylite, updated 5 January 2025. When citing, please name BounceWatch and link this page.